Franklin Resources Inc. Acquires 147,645 Shares of Codexis, Inc. (NASDAQ:CDXS)

Franklin Resources Inc. increased its position in shares of Codexis, Inc. (NASDAQ:CDXS - Free Report) by 501.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 177,101 shares of the biotechnology company's stock after purchasing an additional 147,645 shares during the quarter. Franklin Resources Inc. owned 0.22% of Codexis worth $845,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the company. Kingswood Wealth Advisors LLC bought a new stake in shares of Codexis during the 4th quarter worth approximately $79,000. China Universal Asset Management Co. Ltd. bought a new position in shares of Codexis in the fourth quarter worth about $82,000. Intech Investment Management LLC boosted its stake in shares of Codexis by 55.1% in the 4th quarter. Intech Investment Management LLC now owns 33,111 shares of the biotechnology company's stock valued at $158,000 after purchasing an additional 11,757 shares in the last quarter. Corebridge Financial Inc. grew its holdings in shares of Codexis by 7.2% during the 4th quarter. Corebridge Financial Inc. now owns 40,052 shares of the biotechnology company's stock valued at $191,000 after purchasing an additional 2,703 shares during the last quarter. Finally, Jackson Square Capital LLC acquired a new position in Codexis during the 4th quarter worth approximately $210,000. 78.54% of the stock is currently owned by institutional investors and hedge funds.

Codexis Price Performance

Shares of NASDAQ CDXS traded down $0.01 during midday trading on Friday, reaching $2.11. 557,169 shares of the company were exchanged, compared to its average volume of 658,907. Codexis, Inc. has a one year low of $1.90 and a one year high of $6.08. The stock has a market cap of $174.79 million, a P/E ratio of -2.43 and a beta of 2.35. The company has a quick ratio of 3.15, a current ratio of 3.21 and a debt-to-equity ratio of 0.39. The stock's 50-day moving average price is $2.93 and its 200-day moving average price is $3.85.

Codexis (NASDAQ:CDXS - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The biotechnology company reported ($0.13) EPS for the quarter, missing analysts' consensus estimates of ($0.04) by ($0.09). The business had revenue of $21.46 million for the quarter, compared to analyst estimates of $27.41 million. Codexis had a negative return on equity of 71.56% and a negative net margin of 96.35%. On average, sell-side analysts anticipate that Codexis, Inc. will post -0.77 earnings per share for the current fiscal year.

Codexis Profile

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.